New hope for hard-to-treat colorectal cancer: combo therapy targets stubborn tumors

NCT ID NCT07253896

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Dec 08, 2025 · Last updated Apr 30, 2026 · Updated 25 times

Summary

This study tests whether adding the experimental drug AK104 to standard chemotherapy and either cetuximab or bevacizumab can shrink tumors in people with a specific type of advanced colorectal cancer (MSS type) that has not responded to initial treatment. About 40 adults aged 18-75 with metastatic disease will receive the combination therapy. The main goal is to see how many patients experience a significant reduction in tumor size lasting at least 4 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITING

Hangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SAFETY SAFETY